Acadia Pharmaceuticals
ACAD | NASDAQ
$18.67
-$0.08 (-0.43%)
At close: Nov 16, 2026, 4:00 PM ET
$18.47
-$0.20 (-1.07%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Acadia Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Catherine E. Owen Adams | Chief Executive Officer & Director |
| Carl Segerstrom | Chief People Officer |
| Jennifer J. Rhodes | Executive Vice President, Chief Legal Officer & Secretary |
| Mark C. Schneyer | Executive Vice President & Chief Financial Officer |
| Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications |
| Allyson McMillan Youngblood | Senior Vice President of Rare Disease Franchise |
| Elizabeth Thompson | Executive Vice President and Head of Research & Development |
| James K. Kihara | Senior Vice President of Finance |
| Konstantina Katcheves | Senior Vice President, Chief Business & Strategy Officer |
| Scott Cenci | Senior Vice President, Chief Information & Data Officer |
| Thomas Andrew Garner | Executive Vice President & Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 23, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 144 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 4 | Filing |
Acadia Pharmaceuticals
| Country | United States |
| IPO Date | May 27, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 797 |
| CEO | Catherine E. Owen Adams |
Contact Details
12830 El Camino Real San Diego,
California 92130 United States
Stock Details
| Ticker Symbol | ACAD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070494 |
| CUSIP Number | 004225108 |
| ISIN Number | US0042251084 |
| SIC Code | 2834 |
Recent News
- 7 days ago / businesswire.comAcadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
- 12 days ago / seekingalpha.comAcadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comAcadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
- 12 days ago / marketbeat.comWhat ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
- 20 days ago / zacks.comEarnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
- 1 month ago / zacks.comCan Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
- 2 months ago / zacks.comAcadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
- 2 months ago / businesswire.comAcadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
- 2 months ago / zacks.comACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
- 2 months ago / seekingalpha.comACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Add to Watchlist
Select watchlists to add or remove ACAD